The occurrence of GBM was higher in the BRAF mutation cohort than in the BRAFAMP cohort, whereas the BRAFAMP group had significantly more patients with the IDH1/2, TP53, and ATRX mutations. The gene discussed is ATRX; the disease is glioblastoma.